These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 28164756

  • 1. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
    Arosio D, Manzoni L, Corno C, Perego P.
    Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
    [Abstract] [Full Text] [Related]

  • 2. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
    Sheldrake HM, Patterson LH.
    J Med Chem; 2014 Aug 14; 57(15):6301-15. PubMed ID: 24568695
    [Abstract] [Full Text] [Related]

  • 3. RGD mimetics γ-AApeptides and methods of use (US 20,140,004,039 A1): a patent evaluation.
    Wu H, Jiang J, Xu H, Li Q, Cai J.
    Expert Opin Ther Pat; 2016 Aug 14; 26(1):131-7. PubMed ID: 26560186
    [Abstract] [Full Text] [Related]

  • 4. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
    Rüegg C, Dormond O, Mariotti A.
    Biochim Biophys Acta; 2004 Mar 04; 1654(1):51-67. PubMed ID: 14984767
    [Abstract] [Full Text] [Related]

  • 5. αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
    Dal Corso A, Pignataro L, Belvisi L, Gennari C.
    Curr Top Med Chem; 2016 Mar 04; 16(3):314-29. PubMed ID: 26126915
    [Abstract] [Full Text] [Related]

  • 6. Exploring the Role of RGD-Recognizing Integrins in Cancer.
    Nieberler M, Reuning U, Reichart F, Notni J, Wester HJ, Schwaiger M, Weinmüller M, Räder A, Steiger K, Kessler H.
    Cancers (Basel); 2017 Sep 04; 9(9):. PubMed ID: 28869579
    [Abstract] [Full Text] [Related]

  • 7. RGD-mediated delivery of small-molecule drugs.
    Katsamakas S, Chatzisideri T, Thysiadis S, Sarli V.
    Future Med Chem; 2017 Apr 04; 9(6):579-604. PubMed ID: 28394627
    [Abstract] [Full Text] [Related]

  • 8. Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide.
    Feni L, Parente S, Robert C, Gazzola S, Arosio D, Piarulli U, Neundorf I.
    Bioconjug Chem; 2019 Jul 17; 30(7):2011-2022. PubMed ID: 31243977
    [Abstract] [Full Text] [Related]

  • 9. αvβ3 and α5β1 integrin-specific ligands: From tumor angiogenesis inhibitors to vascularization promoters in regenerative medicine?
    Rocha LA, Learmonth DA, Sousa RA, Salgado AJ.
    Biotechnol Adv; 2018 Jul 17; 36(1):208-227. PubMed ID: 29155160
    [Abstract] [Full Text] [Related]

  • 10. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
    Massaguer A, González-Cantó A, Escribano E, Barrabés S, Artigas G, Moreno V, Marchán V.
    Dalton Trans; 2015 Jan 07; 44(1):202-12. PubMed ID: 25369773
    [Abstract] [Full Text] [Related]

  • 11. Small molecule- and peptide-drug conjugates addressing integrins: A story of targeted cancer treatment.
    Paulus J, Sewald N.
    J Pept Sci; 2024 Jul 07; 30(7):e3561. PubMed ID: 38382900
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
    Dal Corso A, Caruso M, Belvisi L, Arosio D, Piarulli U, Albanese C, Gasparri F, Marsiglio A, Sola F, Troiani S, Valsasina B, Pignataro L, Donati D, Gennari C.
    Chemistry; 2015 Apr 27; 21(18):6921-9. PubMed ID: 25784522
    [Abstract] [Full Text] [Related]

  • 16. The organometallic ferrocene exhibits amplified anti-tumor activity by targeted delivery via highly selective ligands to αvβ3, αvβ6, or α5β1 integrins.
    Ludwig BS, Tomassi S, Di Maro S, Di Leva FS, Benge A, Reichart F, Nieberler M, Kühn FE, Kessler H, Marinelli L, Reuning U, Kossatz S.
    Biomaterials; 2021 Apr 27; 271():120754. PubMed ID: 33756215
    [Abstract] [Full Text] [Related]

  • 17. Targeting integrins for the control of tumour angiogenesis.
    Akalu A, Cretu A, Brooks PC.
    Expert Opin Investig Drugs; 2005 Dec 27; 14(12):1475-86. PubMed ID: 16307488
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Advancement in integrin facilitated drug delivery.
    Arosio D, Casagrande C.
    Adv Drug Deliv Rev; 2016 Feb 01; 97():111-43. PubMed ID: 26686830
    [Abstract] [Full Text] [Related]

  • 20. Peptidomimetics and angiogenesis.
    Mazitschek R, Baumhof P, Giannis A.
    Mini Rev Med Chem; 2002 Oct 01; 2(5):491-506. PubMed ID: 12370049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.